Brain-computer interfaces (BCIs) are no longer just science fiction tools for restoring basic motor control. The field is rapidly expanding into stroke rehabilitation, vision restoration, and even cognitive disorders, with a growing number of companies achieving FDA breakthrough designations. This shift marks a fundamental change in how researchers think about what BCIs can accomplish, moving beyond simple movement restoration to address complex neurological conditions that affect millions of people.

What Are Brain-Computer Interfaces Actually Doing Right Now?

At their core, BCIs create a direct communication pathway between the human brain and external digital systems. Electrical signals produced by neurons are measured, interpreted, and converted into instructions that computers or machines can understand. Unlike traditional interfaces that rely on physical movement like typing or swiping, BCIs respond directly to neural activity itself .

The technology comes in several forms. Invasive BCIs use implanted electrodes to capture brain signals with high precision. Non-invasive BCIs typically use sensors placed on the scalp to detect brainwave activity. Hybrid systems combine neural signals with other physiological inputs, such as eye movement or muscle activity . This variety of approaches means different solutions can be tailored to different medical needs and patient preferences.

The real-world applications are expanding rapidly. In Colorado, neurosurgeons at the University of Colorado Anschutz performed the state's first implanted BCI surgery on a 41-year-old patient who had been paralyzed from the neck down for approximately 10 years following an accident. What makes this case particularly significant is where the device was placed. The physicians implanted the technology in higher-level areas of the brain that allow for more natural and complete sensory and motor control, rather than focusing solely on basic motor regions .

"This surgery is an important step forward not only for this patient but for neuroscience as a whole. While most BCI procedures focus only on purely motor regions, implanting this device in higher-level brain areas will offer new insights into how the human brain works during everyday thinking and movement," said Daniel Kramer, MD, assistant professor of neuroscience at the CU Anschutz School of Medicine and a neurosurgeon at UCHealth.

Daniel Kramer, MD, Assistant Professor of Neuroscience at CU Anschutz School of Medicine

Which Companies Are Getting FDA Approval, and Why Does It Matter?

The FDA's breakthrough device designation is a significant marker of progress in this field. Only a handful of BCI companies worldwide have received this designation, which accelerates the development and review process for devices that address unmet medical needs. In 2024 and 2025, several companies achieved this milestone, signaling that BCIs are moving from experimental research into clinical reality .

CorTec, a German company, became the first German BCI company to receive FDA breakthrough designation for its Brain Interchange system, which is designed to restore movement in individuals who have suffered stroke-related impairments. The device works by using direct cortical electrical stimulation to establish a direct channel of communication between the brain and external rehabilitation technologies. It combines neural signal recording with adaptive stimulation in a closed-loop system, meaning it continuously adjusts based on feedback .

"Only a few BCI companies worldwide, including Neuralink, Synchron, or Blackrock Neurotech, have received Breakthrough Device Designation to date. Achieving this designation is a defining milestone for CorTec and underscores the potential of our Brain Interchange system to address the significant unmet need in stroke rehabilitation," said Frank Desiere, CEO of CorTec.

Frank Desiere, CEO of CorTec GmbH

CorTec successfully implanted its BCI system into two patients at Harborview Medical Center in Seattle as part of an FDA-approved trial. The first implantation occurred in July 2024, with a second patient receiving the implant in February 2025 .

Other companies have also achieved breakthrough designations for different applications:

• Neuralink: Received FDA breakthrough designation for Blindsight, an implant designed to restore vision in individuals who are blind by inserting a microelectrode array into the visual cortex, and for a speech restoration BCI aimed at restoring communication for individuals with severe speech impairment .
• Synchron: Received the designation for its minimally invasive BCI Stentrode, which allows individuals to control digital devices using their thoughts .
• Precision Neuroscience: Won the designation for its Layer 7 Cortical Interface .

How Are Researchers Using BCIs to Study the Brain Itself?

Beyond restoring lost function, BCIs are becoming powerful research tools. The Colorado case is particularly revealing because the device will remain implanted for years, allowing researchers to study how brain signals represent complex cognitive tasks and how they change over time. By gathering detailed data on higher-level brain functions such as learning rules, planning, decision-making, and turning thoughts into action, researchers hope to lay groundwork for future treatments that extend far beyond paralysis .

"Being able to both perform this surgery and collect and analyze long-term data from unique areas of the brain places CU Anschutz and UCHealth at the forefront of brain-computer interface research. Movement and cognition are uniquely linked. With this research program, we will begin to investigate the ways in which the brain generates and governs these processes," said Luke Bashford, PhD, assistant adjunct professor of neuroscience and neurotechnology at the CU Anschutz School of Medicine.

Luke Bashford, PhD, Assistant Adjunct Professor of Neuroscience and Neurotechnology at CU Anschutz School of Medicine

This research could eventually inform new therapies for conditions that affect cognitive control, such as mood disorders or dementia, expanding the potential of brain-computer interfaces well beyond paralysis alone .

What About Non-Invasive Brain-Computer Interfaces?

While implanted BCIs dominate recent headlines, non-invasive approaches are also advancing. BrainCo, a Harvard-incubated startup, demonstrated non-invasive BCI technology that reads neural signals through the skin without requiring surgery. The company has developed algorithms to analyze and understand those signals, offering a safer alternative for some applications .

At a recent HSBC summit, BrainCo showcased a bionic hand controlled through their non-invasive BCI technology. A demonstration showed the device responding to neural signals by moving individual fingers using only thoughts. The company claimed it was the first prosthetic hand in the world capable of controlling each finger individually. The user then played a short piece on a digital piano, demonstrating how the device could handle complex actions .

"For severe brain issues like Parkinson's disease, or for blind people who want to recover sight, you may have to go through surgery. But there are also many other applications where you don't need surgery, like what we do," explained Nyx He, a partner at BrainCo.

Nyx He, Partner at BrainCo

How to Understand the Different Types of BCI Technology

• Invasive BCIs: Use implanted electrodes to capture brain signals with high precision, offering the most accurate signal detection but requiring surgical implantation and carrying risks such as infection or tissue damage .
• Non-invasive BCIs: Typically use sensors placed on the scalp to detect brainwave activity, eliminating surgical risks but generally providing lower signal accuracy and slower processing speeds compared to invasive approaches .
• Hybrid Systems: Combine neural signals with other physiological inputs such as eye movement or muscle activity, offering flexibility in how brain signals are captured and interpreted .

What Challenges Still Need to Be Solved?

Despite rapid progress, significant obstacles remain. Modern non-invasive BCIs still struggle with low signal accuracy and slow processing speeds. Electrode-based implanted models are more reliable but carry surgical risks. Ethical considerations dominate discussions about who owns neural data and what safeguards protect users' thoughts and private intentions. Since BCIs record direct brain activity, privacy concerns extend far beyond standard data protection .

Accessibility and affordability present another major hurdle. High-end BCI technology devices remain experimental and expensive, limiting widespread consumer use. Integrating this technology seamlessly into daily life will require breakthroughs in safe materials, power efficiency, and data interpretation. Many experts estimate that BCIs will initially appear in specialized fields such as rehabilitation therapies, assistive healthcare, and certain professional workflows before entering consumer markets, with this transition potentially taking another decade .

The convergence of breakthrough FDA designations, successful human implants, and expanding applications suggests that brain-computer interfaces are transitioning from experimental research into clinical practice. What started as a tool for restoring basic motor function is evolving into a platform for treating stroke recovery, restoring vision, improving speech, and even understanding how the brain itself works. For patients with neurological injuries or degenerative conditions, this expansion of BCI capabilities represents genuine hope for regaining lost abilities and independence.